Tremendous rebuttal by georgejj to an argument tha
Post# of 72440
George came back with why the trial was terminated, because another was started where the treatment was based on the patients weight, and therefore was much more effective and safer. Well, the replacement trial showed IL-20 was a tremendous treatment against arthritis. He also showed that Prurisol is much safer and more effective than the biologic used in the replacement trial due to its chemical makeup.
From georgejji:
That trial was not a failure. The trial was terminated NCT01636817 because another trial had started with the subcutaneous dose titrated to the body weight of each subject in the trial. Titration of the dose to each subjects body weight is a much safer and effective method of treatment.
https://clinicaltrials.gov/show/NCT01282255
The results of the new trial with the dose titrated to each trial subject's body weight is that the NNC0109-0012, a selective anti-IL-20 recombinant human monoclonal antibody (mAb) both safe and very effective.
Quote:
In this phase IIa trial, treatment with NNC0109-0012 (anti-IL-20 mAb) was effective in patients with seropositive RA as early as week 1, with further improvements to week 12. No safety or tolerability concerns were identified with weekly NNC0109-0012 administration.
http://onlinelibrary.wiley.com/doi/10.1002/art.39083/full
Prurisol is not a monoclonal antibody and is taken oarally. Prurisol is much safer and more effective.